Effects of bile acid sequestration on hepatic steatosis in obese mice
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 1
Abstract
Background. Bile acid sequestration (BAS) with resins has shown antidiabetic effects in both humans and animals. Since hepatic steatosis is commonly associated with type 2 diabetes mellitus and the effects of BAS on steatosis have not been explored in detail, we evaluated the effects of cholestyramine (CTM) administration on fatty liver development in the leptin-deficient obese mice. Aim. To study the effects of BAS on fatty liver development in obese (ob/ob) mice. Material and methods. 4 week-old ob/ob mice (B6.V-Lepob/J, n = 4-6 per group) were fed with or without CTM (control group) during 8 weeks. Serum and biliary parameters, glucose tolerance test (GTT), hepatic triglyceride content, liver histology and hepatic gene expression of relevant genes related to bile secretion, lipid and glucose metabolism were assessed. Results. Control 12-week-old mice exhibited marked obesity and hepatic steatosis. CTM administration expectedly determined a marked de-repression of 7-α-hydroxylase and decreased biliary bile acid secretion as well as improved GTT. CTM feeding showed no effects on hepatic triglyceride content or in the degree of steatosis on liver histology. CTM was associated with increased levels of serum alanine-aminotransferase. Conclusion. Although CTM administration positively affects glucose tolerance it does not prevent hepatic steatosis development in obese mice. Moreover, CTM feeding was associated to liver enzyme elevation in this model of NAFLD. Thus, the effects BAS on NAFLD need to be specifically addressed since this therapy might not be beneficial for this condition.
Authors and Affiliations
Nancy Solís, Margarita Pizarro, Pablo Quintero, Juan Pablo Arab, Arnoldo Riquelme, Oslando Padilla, Gonzalo Carrasco, Carlos J. Pirola, Silvia Sookoian, Marco Arrese
Keywords
Related Articles
- EP ID EP78363
- DOI -
- Views 148
- Downloads 0
Hepatogenous diabetes. Current views of an ancient problem
Diabetes developed as a complication of cirrhosis is known as hepatogenous diabetes» (HD). Around 30% to 60% of cirrhotic patients suffer from this metabolic disorder. Insulin resistance in muscular, hepatic and adipose...
Noninvasive markers of liver fibrosis in Latin America and Mexico
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C
Should donation after cardiac death liver grafts be used for retransplantation?
Introduction. Donation after cardiac death (DCD) donors provide an important source of livers that has been used to expand the donor pool. As a consequence of increased numbers of OLT, allograft failure due to early and...
Congenital double intrahepatic portosystemic shunt: Imaging findings and endovascular closure